Shares of Bausch + Lomb Corp. (BLCO) surged 13.88% in pre-market trading on Wednesday following the release of its third-quarter earnings report, which exceeded analyst expectations and showcased the company's strong performance in the eyecare market.

The eye health company reported adjusted earnings per share of $0.18 for Q3, surpassing the analyst consensus estimate of $0.16 by 12.5%. This represents a significant improvement from $0.13 per share in the same period last year. Revenue for the quarter came in at $1.28 billion, meeting Wall Street expectations and marking a 7.1% increase year-over-year.

Bausch + Lomb's CEO, Brent Saunders, expressed confidence in the company's strategic direction, stating, "We're delivering on the vision we laid out in 2023, with a base business engine that continues to hum and steady introduction of innovative products across categories." This optimism was reflected in the company's decision to maintain its full-year 2025 revenue guidance at $5.05 billion to $5.15 billion, in line with analyst projections of $5.09 billion.

Investors were particularly encouraged by the company's EBITDA outlook. Bausch + Lomb guided for full-year EBITDA of $890 million at the midpoint, surpassing analyst estimates of $872.5 million. This positive forecast, combined with the earnings beat and steady revenue growth, likely contributed to the stock's significant pre-market rally.

The strong quarterly performance and optimistic outlook suggest that Bausch + Lomb's strategic initiatives and product innovations are gaining traction in the competitive eyecare market. As the company continues to build on its nearly 170-year history in vision care and eye health innovation, investors appear increasingly confident in its growth prospects and market position.